YALE UNIVERSITY
Tumor and immune determinants of effective anti-tumor immunity in renal cell carcinoma
Tumor and immune determinants of effective anti-tumor immunity in renal cell carcinoma is a funding opportunity from YALE UNIVERSITY, up to 661522, closing June 30, 2028.
Jun 30, 2028
(700d left)Overview
PROJECT SUMMARY Immune checkpoint inhibitors (ICIs) targeting the PD-1 pathway have transformed the management of many advanced cancers, including renal cell carcinoma (RCC), but most patients do not receive durable benefit from these treatments. Whereas many efforts to understand ICI response and resistance in other…